AbbVie raises 2026 EPS guidance, posts Q3 revenue gain, advances pipeline
Quarterly growth came alongside the closed Apogee Therapeutics deal, new FDA approvals for Skyrizi and Juvmo, and positive late-stage data in HS and DLBCL.
AbbVie reported third-quarter 2026 results on October 30, 2026. The company reported worldwide net revenues of $17.404 billion, an increase of 10.3 percent on a reported basis, or 10.5 percent on an operational basis.1
On the pipeline side, AbbVie said it completed its acquisition of Apogee Therapeutics, adding assets targeting dermatologic, respiratory and other inflammatory and immunological diseases, including zumilokibart, a late-stage, half-life extended monoclonal antibody targeting IL-13 for atopic dermatitis, and APG273, a long-acting combination candidate targeting IL-13 and TSLP in asthma.1
Two approvals arrived during the quarter. The FDA approved Skyrizi (risankizumab) for subcutaneous induction in moderately to severely active Crohn's disease, supported by positive data from the Phase 3 AFFIRM study.1 Separately, the FDA approved Juvmo (tavapadon) tablets as the only selective D1/D5 receptor agonist for Parkinson's disease, taken once daily with or without levodopa, supported by the Phase 3 TEMPO program, which showed significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profile.1
On trial readouts, AbbVie reported positive topline results from the Phase 3 INTREPID study of lutikizumab in moderate to severe hidradenitis suppurativa, which met its primary endpoint of HiSCR 75 at Week 16 versus placebo and most ranked secondary endpoints, with no new safety concerns identified.1 AbbVie and Genmab also reported that the Phase 3 EPCORE DLBCL-2 trial of fixed-duration Epkinly plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma showed a statistically significant and clinically meaningful improvement in progression-free survival, reducing the risk of disease progression or death by 51 percent.1
On guidance, AbbVie said it is raising its adjusted diluted EPS guidance for the full year 2026 to a range of $13.95 to $13.99, from a prior range of $13.76 to $13.96, a figure that includes a $0.69 per share unfavorable impact from acquired IPR&D and milestones expense booked through the third quarter.1 The board also approved a quarterly dividend increase to $1.82 per share from $1.73, effective with the payment scheduled for February 16, 2027 to shareholders of record on January 15, 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.